Kyowa Kirin Co Ltd ADR KYKOY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KYKOY is a good fit for your portfolio.
News
-
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome
-
Kyowa Kirin Announces Acceptance of Abstract for Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting 2024
-
Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024
-
Kyowa Kirin Announce Symposium, Acceptance of Abstract for Presentation at American Academy of Dermatology 2024 Meeting
-
Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema
Trading Information
- Previous Close Price
- $19.68
- Day Range
- $19.80–19.80
- 52-Week Range
- $15.60–19.80
- Bid/Ask
- $10.40 / $26.70
- Market Cap
- $10.64 Bil
- Volume/Avg
- 288 / 1,155
Key Statistics
- Price/Earnings (Normalized)
- 14.53
- Price/Sales
- 3.38
- Dividend Yield (Trailing)
- 0.58%
- Dividend Yield (Forward)
- 0.58%
- Total Yield
- 0.58%
Company Profile
Kyowa Kirin Co Ltd is a drug manufacturing company that focuses on biologic medicines. Its operations emphasize four categories: nephrology, oncology, immunology and allergy, and the central nervous system. The company has two reportable segments, Pharmaceuticals and Biochemicals. The pharmaceuticals business manufactures and sells ethical pharmaceuticals, diagnostic reagents, and other products. The biochemicals business manufactures and sells raw materials for pharmaceutical and industrial use, mainly amino acids, nucleic acids and related compounds, healthcare products, and others.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Growth
- Total Number of Employees
- 5,974
- Website
- http://www.kyowa-kirin.com
Comparables
Valuation
|
Metric
|
KYKOY
|
4516
|
4554
|
|---|---|---|---|
Price/Earnings (Normalized) | 14.53 | 11.88 | 7.72 |
Price/Book Value | 1.79 | 1.37 | 0.92 |
Price/Sales | 3.38 | 2.00 | 0.93 |
Price/Cash Flow | 12.00 | 11.83 | 3.99 |
Price/Earnings
KYKOY
4516
4554
Financial Strength
|
Metric
|
KYKOY
|
4516
|
4554
|
|---|---|---|---|
Quick Ratio | 3.93 | 4.17 | 0.68 |
Current Ratio | 4.59 | 5.92 | 1.46 |
Interest Coverage | 487.17 | 256.02 | 55.27 |
Quick Ratio
KYKOY
4516
4554
Profitability
|
Metric
|
KYKOY
|
4516
|
4554
|
|---|---|---|---|
Return on Assets (Normalized) | 9.10% | 9.57% | 3.39% |
Return on Equity (Normalized) | 11.18% | 11.30% | 7.02% |
Return on Invested Capital (Normalized) | 10.39% | 10.97% | 4.22% |
Return on Assets
KYKOY
4516
4554
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Jvqvsjgb | Bvy | $698.5 Bil | |
JNJ
| Johnson & Johnson | Nhqhpwp | Zkmts | $359.2 Bil | |
MRK
| Merck & Co Inc | Wqvtpxszn | Pwt | $323.0 Bil | |
ABBV
| AbbVie Inc | Rlrgchmb | Qnwn | $289.2 Bil | |
AZN
| AstraZeneca PLC ADR | Drjyxpqsp | Zkfck | $236.3 Bil | |
NVS
| Novartis AG ADR | Mffmkhq | Ffmft | $197.3 Bil | |
RHHBY
| Roche Holding AG ADR | Tznnygxzfj | Kvxxt | $192.5 Bil | |
AMGN
| Amgen Inc | Dqblbdpbjd | Lwdnf | $167.0 Bil | |
PFE
| Pfizer Inc | Kfnbrzdzb | Yrpy | $157.5 Bil | |
SNY
| Sanofi SA ADR | Gdxlyvprd | Yxpv | $122.3 Bil |